Key Highlights

  • Craneware plc (LSE:CRW) published FY2026 final results on 21 September 2026 showing Revenue of $206.0 million, almost unchanged from $205.7 million.
  • Adjusted EBITDA rose 2.9% to $67.1 million, with the Margin improving to 33%, while operating cash conversion reached 98%.
  • Annual Recurring Revenue edged up to $185 million, but net revenue retention fell to 100% from 107%.
  • Management set a planning basis of roughly $185 million of revenue for FY2027, a material reset.
  • Shares fell sharply on the results and were down about 46% year to date at that point, following two profit warnings in three months.

Craneware plc (LSE:CRW), the Edinburgh-based provider of financial performance software to US hospitals and a constituent of the FTSE AIM All-Share, remains one of the most debated healthcare technology stocks in London on 4 November 2026. Once regarded as a dependable compounder with high recurring revenue and strong margins, the group has had a difficult 2026, and investors are now trying to decide whether the shares represent deep value or a Business whose growth model has been permanently damaged.

Why Craneware Is in Focus Today

Attention on LSE:CRW remains elevated following its September results, which confirmed that growth had stalled. On the day of the release, the shares traded around £10.25 to £10.44, roughly 22% to 24% lower, valuing the company at about £354 million. The decline built on an earlier warning in July, meaning the market has absorbed two downgrades in quick succession.

The numbers themselves present a contradiction. The existing business remains profitable and highly cash generative, with adjusted EBITDA of $67.1 million and a 33% margin. Yet revenue was essentially flat and net revenue retention dropped to 100%, meaning upsell to existing customers no longer outpaced churn and contraction. For a software company valued partly on future expansion, that change carries significant weight.

The 340B Opportunity Converts Slowly

A key driver of the downgrade was slower-than-expected conversion of 340B-related activity into revenue. The US 340B Drug Pricing Program allows eligible hospitals to buy outpatient drugs at discounted prices, and Craneware's software helps hospitals manage compliance and capture savings. Management estimates around $500 million of qualifying drug purchases remain linked to its opportunity, but changing pharmaceutical manufacturer restrictions and deferred enterprise contracts have made revenue timing far less predictable.

Chief executive Keith Neilson acknowledged that FY2026 was challenging and that growth fell short of expectations. The company believes changing 340B conditions could become more supportive over time, but that depends on regulatory clarity and customer adoption.

Cybersecurity Incident Adds Uncertainty

In July 2026, Craneware plc (LSE:CRW) disclosed a Cybersecurity incident involving unauthorised access to part of its data environment. Files including some employee, customer and partner records were accessed and taken. The company said the incident was contained and core customer services were not disrupted. However, the full financial impact has not yet been quantified. For a healthcare software provider, trust is central, so investors are watching closely for any sign of customer losses, remediation costs or regulatory consequences.

FY2027 Priorities and Cost Reset

Management has outlined clear priorities for the 2027 financial year: renewing long-term customer contracts, expanding recurring revenue, resizing the cost base, maintaining strong cash generation and building a platform for renewed growth beyond FY2027. The planning basis of around $185 million of revenue implies a meaningful step down from FY2026, which explains why the market reacted so sharply.

The company has also been active in returning cash. A share buyback of up to $25 million was launched in March 2026, and chair Will Whitehorn bought shares in July. Customer retention remains above 90%, and the business retains Liquidity and borrowing capacity, reducing near-term financial risk.

The Bull and Bear Debate

Supporters of LSE:CRW point to $185 million of annual recurring revenue, a 33% EBITDA margin, cash conversion close to 100% and an established position in the complex US hospital finance market. At a Market Value well below its historical levels, they argue that a lot of bad news is already priced in. Brokers had previously held buy ratings with targets well above current levels, though those targets predate the latest results and may be revised.

Sceptics counter that repeated forecast misses raise questions about management credibility and visibility. Flat revenue, falling retention and the cyber incident together suggest Craneware should no longer be valued as a predictable compounder until growth returns.

What Investors Are Watching Next

The next major checkpoint for Craneware plc (LSE:CRW) is its first-half trading update for the six months to 31 December 2026, typically released in January, followed by interim results expected in early March 2027. Investors will focus on annual recurring revenue growth, net revenue retention, contract renewals and progress in converting 340B opportunities into revenue.

Other watch points include the cost-reduction programme, any quantified costs from the cyber incident, progress on the buyback, broker forecast revisions and possible insider purchases. Takeover speculation could also surface, as lower valuations in UK-listed software often attract Private Equity interest. Any evidence that FY2027 revenue is tracking at or above the $185 million planning basis would be a meaningful positive for sentiment on the FTSE AIM All-Share.

Bottom Line

Craneware plc (LSE:CRW) is not a broken business. It remains profitable, cash generative and embedded with US hospitals. But two profit warnings, stalled growth and a cyber incident have changed how the market views it. Until recurring revenue and retention improve, LSE:CRW is likely to be treated as a higher-risk recovery situation rather than a premium-rated growth stock.